Using the Adeno-associated virus (AAV) as a gene delivery vehicle, we have constructed a recombinant vector containing the full length rat preproinsulin gene . Utilizing the well described non-obese diabetic (NOD) mouse model, an experimental group (n 10) of animals were intramuscularly (IM) injected with 107 rAAV virions containing the insulin gene and compared to a mock-injected control group (n 10). Blood glucose (glc) was then measured weekly for 16 weeks. Data showed that the experimental group contained 70% euglycemic animals (defined as glc <200mg/dL) versus 10% of the control animals (P<.05) at 14 weeks. Mean weight in the treated group was greater than the untreated group. Insulin mRNA was detected at the injection site of all of the treated animals, but not controls. Complete destruction of islets was confirmed by histology ruling out the possibility of spontaneous reversal of insulinitis. We conclude that IM delivery of the insulin gene in the NOD mouse was able to prevent clinical DM up to 14 weeks in a majority of treated animals. Our experimental data suggests that gene therapy may be an alternative treatment for IDDM in the future.
INTRODUCTION
Diabetes Mellitus (DM) in humans is the result of either lack of insulin (Type I) or insulin resistance (Type II). The impact of DM on morbidity and mortality is considerable. Since the discovery of insulin, DM is considered a manageable disease, however, secondary complications of DM are considerable and lead to significant morbidity and mortality. Alternative 1C) showed that the majority of experimental animals maintained glc levels below the cutoff (70% at 14 weeks vs. 10% of the controls).
In addition to improved glc levels, vLP-1-injected animals had a higher mean weight (Fig. 2) , and appeared visibly more healthy than controls (Fig. 3) . At 16 were sacrificed and various tissues were examined by hematoxylin and eosin (H&E) staining. The degree of insulinitis in control and experimental animals was found to be equal (Fig. 4A ). In addition, there was no evidence of immune infiltrate at the injection site or in other tissues (Fig. 4B) . We stained islets of rAAV injected animals with anti-insulin antibody and found that insulin producing beta cells were not seen in these islets (Fig. 4C) . Figure 4D represents Other exogenously administered agents such as Linomide [13] and certain specific peptides [14] were also effective in preventing DM in NOD mice. Finally, introduction of gene mutations and MHC Class II genes also resulted in the prevention of DM in the NOD mice. [15, 16] Another method of preventing DM is by supplying an alternative source of insulin such as by pancreatic islet transplants. Transplantation of islets utilizing semi-permeable membranes was partially successful in the prevention of DM. [17] Pretreatment of islets with various compounds also prolonged islet survival but did not impact the insulinitis. I181 The limitations of allogeneic islet cell transplantation in NOD are no different than that seen in humans, including the need of immunosuppressive agents.
In these experiments, we have provided an endogenous source of insulin by injecting the insulin gene into the skeletal muscle. Insulin released from the muscle tissues was adequate to prevent DM. We found mRNA by RT-PCR at the site of injection without obvious pathological damage to the muscle or other organs. The degree of insulinitis in NOD mice receiving vLP-1 was similar to controls despite the fact that blood glc and weight of vLP-l-injected animals was near-normal. These results suggested that vLP-1 produced insulin did not prevent the development of insulinitis. Our results are in contrast to that of Jansen et al. [9] 
